Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States
Significant rwOS benefits were identified in men who received Ra-223 as an earlier line of therapy, received Ra-223 in combination with another therapy, and completed ≥5 Ra-223 cycles, underscoring the importance of Ra-223 in the current treatment landscape.
Authors
- Yiqiao Zhang (ORCID: https://orcid.org/0000-0003-4240-1614)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Matthew J. Korn
- Amit D. Raval (ORCID: https://orcid.org/0000-0001-8265-8612)
- Niculae Constantinovici
Institutions
- Bayer (United States) (US)
- University of California San Diego (US)
- Bayer (Switzerland) (CH)
- University of California San Diego Medical Center (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1038/s41391-025-00969-6
- Citations
- 8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Bayer
- Exelixis